In vivo effector functions of high-affinity mouse IgG receptor FcγRI in disease and therapy models.

Gillis, CM; Zenatti, PP; Mancardi, DA; Beutier, H; Fiette, L; Macdonald, LE; Murphy, AJ; Celli, S; Bousso, P; Jönsson, F; Bruhns, P

In vivo effector functions of high-affinity mouse IgG receptor FcγRI in disease and therapy models.

Gillis, CM Zenatti, PP Mancardi, DA Beutier, H Fiette, L Macdonald, LE Murphy, AJ Celli, S Bousso, P Jönsson, F Bruhns, P

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Journal of Autoimmunity, 2017, 80, pp. 95-102
Issue Date:: 2017-06

Closed Access

	Filename	Description	Size
	1-s2.0-S0896841116301834-main.pdf		1.08 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Gillis, CM
dc.contributor.author	Zenatti, PP
dc.contributor.author	Mancardi, DA
dc.contributor.author	Beutier, H
dc.contributor.author	Fiette, L
dc.contributor.author	Macdonald, LE
dc.contributor.author	Murphy, AJ
dc.contributor.author	Celli, S
dc.contributor.author	Bousso, P
dc.contributor.author	Jönsson, F
dc.contributor.author	Bruhns, P
dc.date.accessioned	2022-08-31T02:40:32Z
dc.date.available	2016-09-22
dc.date.available	2022-08-31T02:40:32Z
dc.date.issued	2017-06
dc.identifier.citation	Journal of Autoimmunity, 2017, 80, pp. 95-102
dc.identifier.issn	0896-8411
dc.identifier.issn	1095-9157
dc.identifier.uri	http://hdl.handle.net/10453/161127
dc.description.abstract	Two activating mouse IgG receptors (FcγRs) have the ability to bind monomeric IgG, the high-affinity mouse FcγRI and FcγRIV. Despite high circulating levels of IgG, reports using FcγRI-/- or FcγRIV-/- mice or FcγRIV-blocking antibodies implicate these receptors in IgG-induced disease severity or therapeutic Ab efficacy. From these studies, however, one cannot conclude on the effector capabilities of a given receptor, because different activating FcγRs possess redundant properties in vivo, and cooperation between FcγRs may occur, or priming phenomena. To help resolve these uncertainties, we used mice expressing only FcγRI to determine its intrinsic properties in vivo. FcγRIonly mice were sensitive to IgG-induced autoimmune thrombocytopenia and anti-CD20 and anti-tumour immunotherapy, but resistant to IgG-induced autoimmune arthritis, anaphylaxis and airway inflammation. Our results show that the in vivo roles of FcγRI are more restricted than initially reported using FcγRI-/- mice, but confirm effector capabilities for this high-affinity IgG receptor in vivo.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier
dc.relation.ispartof	Journal of Autoimmunity
dc.relation.isbasedon	10.1016/j.jaut.2016.09.009
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1107 Immunology
dc.subject.classification	Immunology
dc.subject.mesh	Animals
dc.subject.mesh	Antibodies, Blocking
dc.subject.mesh	Antibody Affinity
dc.subject.mesh	B-Lymphocytes
dc.subject.mesh	Disease Models, Animal
dc.subject.mesh	Hepatectomy
dc.subject.mesh	Humans
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Mice
dc.subject.mesh	Mice, Inbred C57BL
dc.subject.mesh	Mice, Knockout
dc.subject.mesh	Purpura, Thrombocytopenic, Idiopathic
dc.subject.mesh	Receptors, IgG
dc.subject.mesh	Splenectomy
dc.subject.mesh	Animals
dc.subject.mesh	Antibodies, Blocking
dc.subject.mesh	Antibody Affinity
dc.subject.mesh	B-Lymphocytes
dc.subject.mesh	Disease Models, Animal
dc.subject.mesh	Hepatectomy
dc.subject.mesh	Humans
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Mice
dc.subject.mesh	Mice, Inbred C57BL
dc.subject.mesh	Mice, Knockout
dc.subject.mesh	Purpura, Thrombocytopenic, Idiopathic
dc.subject.mesh	Receptors, IgG
dc.subject.mesh	Splenectomy
dc.subject.mesh	B-Lymphocytes
dc.subject.mesh	Animals
dc.subject.mesh	Mice, Inbred C57BL
dc.subject.mesh	Mice, Knockout
dc.subject.mesh	Humans
dc.subject.mesh	Mice
dc.subject.mesh	Purpura, Thrombocytopenic, Idiopathic
dc.subject.mesh	Disease Models, Animal
dc.subject.mesh	Receptors, IgG
dc.subject.mesh	Antibodies, Blocking
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Hepatectomy
dc.subject.mesh	Splenectomy
dc.subject.mesh	Antibody Affinity
dc.title	In vivo effector functions of high-affinity mouse IgG receptor FcγRI in disease and therapy models.
dc.type	Journal Article
utslib.citation.volume	80
utslib.location.activity	England
utslib.for	1107 Immunology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2022-08-31T02:40:31Z
pubs.publication-status	Published
pubs.volume	80

Abstract:

Two activating mouse IgG receptors (FcγRs) have the ability to bind monomeric IgG, the high-affinity mouse FcγRI and FcγRIV. Despite high circulating levels of IgG, reports using FcγRI-/- or FcγRIV-/- mice or FcγRIV-blocking antibodies implicate these receptors in IgG-induced disease severity or therapeutic Ab efficacy. From these studies, however, one cannot conclude on the effector capabilities of a given receptor, because different activating FcγRs possess redundant properties in vivo, and cooperation between FcγRs may occur, or priming phenomena. To help resolve these uncertainties, we used mice expressing only FcγRI to determine its intrinsic properties in vivo. FcγRIonly mice were sensitive to IgG-induced autoimmune thrombocytopenia and anti-CD20 and anti-tumour immunotherapy, but resistant to IgG-induced autoimmune arthritis, anaphylaxis and airway inflammation. Our results show that the in vivo roles of FcγRI are more restricted than initially reported using FcγRI-/- mice, but confirm effector capabilities for this high-affinity IgG receptor in vivo.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/161127